相关实验视频

Updated: May 31, 2025

Evaluating In Vitro DNA Damage Using Comet Assay

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

在非典型癌类药物患者的capecitabine和单独的temozolomide或temozolomide

Linda Galvani¹, Arianna Zappi¹, Sara Pusceddu²

¹Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - Università di Bologna, Bologna, Italy.

|January 24, 2025

概括

与单独使用temozolomide (TEM) 相比,capecitabine加temozolomide (CAPTEM) 化疗显示了较好的无进展生存期 (PFS),用于高级非典型癌 (AC). 需要进一步的研究来证实肺部神经内分泌瘤中的这些发现.

科学领域:

在瘤学瘤学.
医学研究医学研究
临床试验临床试验

背景情况:

肺部神经内分泌瘤 (NENs) 约占肺癌的20%.
对于非典型的癌类药物 (ACs) 存在有限的治疗选择.
单剂特莫索洛米德 (TEM) 在肺NEN中表现出活性.

研究的目的:

研究基于TEM的疗法 (TEM与capecitabine加上temozolomide [CAPTEM]) 在晚期AC患者的疗效.
为了比较TEM和CAPTEM治疗之间的无进展生存率 (PFS),整体反应率 (ORR) 和整体生存率 (OS).

主要方法:

从2003年1月至2023年1月期间接受AC治疗的患者前性收集数据的回顾性分析.
患者接受了TEM或CAPTEM作为任何治疗线.
主要终点:PFS;次要终点:ORR和OS.

主要成果:

这项研究包括31名晚期AC患者 (17名CAPTEM,14名TEM).
与TEM (15.5个月) 相比,CAPTEM (33.9个月) 的PFS中位数显著更长 (p=0.047).
与TEM相比,CAPTEM治疗独立地与进展风险降低有关.

结论:

在晚期AC患者中,开普西他加泰莫索洛米德 (CAPTEM) 治疗与比单独使用泰莫索洛米德 (TEM) 更长的PFS有关.
需要进行更大规模的前性研究来验证这些发现.
这项研究有助于了解晚期肺AC的治疗选择.

关键词:

非典型的癌类药物卡普特姆 (CAPTEM) 的意思是化疗化疗是一种化学疗法.肺部神经内分泌瘤是肺部的神经内分泌瘤.这就是TEMEM.

更多相关视频

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...